This is done to avoid missing them as a result of the germline subtraction performed during the tumor analysis (i.e., a potential BRCA1 loss of function mutation present both in an ovarian cancer and in the germline sequence). This evidence concerns the gene BRCA1 and ovarian carcinoma.